Roy D. Baynes - 14 Aug 2026 Form 4 Insider Report for Aardvark Therapeutics, Inc. (AARD)

Reporting relationship: Director
Issuer ticker: AARD
Reported as of: 14 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Aug 2026, 19:45:28 UTC
Prior SEC filing: 30 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Nelson Sun, as Attorney-in-Fact

Key filing fact

Roy D. Baynes filed Form 4 for Aardvark Therapeutics, Inc. (AARD) on 21 Aug 2026.

Key facts

This page summarizes Roy D. Baynes's Form 4 filing for Aardvark Therapeutics, Inc. (AARD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Aug 2026, 19:45.

Change

Previous filing in this sequence was filed on 30 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001680739 Primary reporting owner

Baynes Roy D.

Relationship: Director
Address: C/O AARDVARK THERAPEUTICS, INC., 4370 LA JOLLA VILLAGE DRIVE, SUITE 1050, SAN DIEGO
Signature: /s/ Nelson Sun, as Attorney-in-Fact
Signature date: 21 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AARD transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +44,964
Change %
Price: $0.000000^*
Shares after: 44,964
Date: 14 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 44,964
Exercise price: $6.54
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option shall vest in full on the earlier of (i) August 14, 2027, and (ii) immediately prior to the Registrant's next Annual Meeting of Stockholders following the date of grant, subject to the Reporting Person's continuous service through the applicable vesting date, inclusive.